Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 16/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 3/20 | 0.34 |
| ▸ | BCR | P11274 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087603 | 0.90 | GRM4 (0.36) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL4095384 | 0.89 | GRM4 (0.41) | GRM4KCNH2HTR2BMTNR1ADYRK1B | |
| SCHEMBL4082428 | 0.89 | ABL1 (0.37) | GRM4KCNH2ABL1BCR | |
| SCHEMBL4082704 | 0.89 | GRM4 (0.42) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL4088864 | 0.89 | GRM4 (0.42) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL4092722 | 0.86 | GRM4 (0.51) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL4087912 | 0.84 | MAPK1 (0.35) | GRM4KCNH2 | |
| SCHEMBL4088815 | 0.84 | GRM4 (0.40) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL4093448 | 0.82 | GRM4 (0.36) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL4082073 | 0.81 | GRM4 (0.34) | GRM4KCNH2HTR2BMTNR1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-8415362-B2 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | GRM4 2958/4885KCNH2 3465/4885HTR2B 2931/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | GRM4 2958/4885KCNH2 3465/4885HTR2B 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.